•
Pluripotential stem cells
•
Progenitor cells committed to specific cell lineages
•
Precursor cells recognizable in the bone marrow
A. General
Several growth factors act cooperatively at each of the different stages of hematopoietic cell
development. Some growth factors (eg, stem cell factor (SCF) and IL-3), tend to act at
earlier stages and on multiple cell lineages; others, like erythropoietin and thrombopoietin,
act on later, more differentiated progenitor and precursor cells that are committed a single
lineage.
* These are generalization since many of these factors act at different phases of hematopoiesis
and on multiple cell lineages.
A. Common Features:
B. Diseases:
Aplastic anemia
B. G-CSF, GM-CSF
4. Increase WBC and combat infections in various congenital and acquired causes
of neutropenia, including aplastic anemia, myelodysplasia, drug-induced
agranulocytosis.
C. IL-3, usually in combination with another growth factor such as C- or GM-CSF. Not
in wide clinical use. Has been tried in several of the situations outlined for G-, GM-
CSF, hoping for multi-lineage (WBC, RBC, and platelet) response. Only partly
successful to date.
D. IL-6, IL-11. In trials to determine whether they will hasten platelet recovery after
chemotherapy, BMT.
APLASTIC ANEMIA
Etiology: Idiopathic
Radiation-induced
Lack of anchoring protein - decreased membrane proteins including delay accelerating factor
(DAF), causing increased sensitivity to 1ysis by complement.
Frequently pancytopenia (Pig-a and DAF defect present in RBCs, neutrophils, platelets,
lymphocytes, endothelial cells).
Thrombotic complications
Renal abnormalities
Diagnosis: sugar water (sucrose hemolysis) test, acid hemolysis (Ham) test, tests for deficiency of
DAF and other anchored proteins
Associations: PNH defect may be seen in other disorders with damaged stem cells (aplastic
anemia, MPD, MDS, AML); PNH patients may develop AML
Myelodysplastic Syndrome
"Dyspoietic" marrow cells, giving rise to "dysplastic" peripheral blood cells (ringed sideroblasts,
Pelger cells, etc.)
Treatment: EPO for anemia, G-CSF for neutropenia. Allogeneic bone marrow transplantation
may be curative
Acute promyelocytic leukemia: All-trans retinoic acid leads to improved survival, causes
promyelocytes to differentiate into mature neutrophils
Adult AML: Consolidation therapy with high dose cytosine arabinoside, after remission induction,
improves survival
Acute myelogenous leukemia: differentiation blocked at or near the level of the myeloblast
(marrow filled with blasts, with few normal precursor cells; normal peripheral blood cells
decreased with variable numbers of blasts)
I. Allogeneic: replace abnormal stem cells by normal stem cells from histocompatible marrow
donor. Also permits high dose chemotherapy, XRT before marrow is transplanted.
Aplastic anemia
II. Autologous: Permits high dose chemotherapy, XRT, before patient's own cryopreserved
marrow cells are reinfused.
Acute leukemia, other malignancies that are in remission or do not involve the marrow
III. Trend toward use of peripheral blood rather than BM stem cells
References
2. Baranski Bet al: Epstein-Barr virus in the bone marrow of patients with aplastic anemia.
Ann Intern Med 109:695, 1988
3. Bradley TR., and Metcalf D. The growth of mouse bone marrow cell in vitro. Aust J Exp
Med Sci. 44:287, 1966
6. Eschbach JW et al. Correction of the anemia of end-stage renal disease with recombinant
human erythropoietin: Results of a combined Phase I and II clinical trial. N Engl J Med.
316:73, 1987.
7. Groopman, JEet al: Hematopoietic growth factors: biology and clinical applications. N
Engl J Med 321:1449, 1989
10. Storb R, Thomas ED, Buckner CD et al: Marrow transplantation for aplastic anemia.
Sem Hematol 21:53, 1984.
11. Till JE and McCulloch EA. A direct measurement of the radiation sensitivity of
mouse bone marrow cells. Radiat Res. 14:213, 1961.
12. Young NS, Alter BF: Aplastic anemia, Acquired and Inherited. WB Saunders.
Philadelphia, 1994.